The purpose of this study is to determine if SAR156597 given by subcutaneous injection (injection under the skin) for up to 6 weeks (total of 7 injections), is safe compared to placebo (an inactive solution injection).
SAR156597 is a type of drug called monoclonal antibody (a type of protein) that blocks specific chemicals in your body. SAR156597 is an investigational drug that has not been approved for marketing by the health authorities.
Participants in this study will be randomly (by chance; similar to a flip of a coin) assigned to receive 1 of 3 doses of SAR156597 (50 mg, 100 mg, or up to 200 mg per injection) or placebo.
Your participation in this study may last up to 22 weeks and include 12 study visits.
The objective of this study is to obtain retrospective case data from digital chest x-ray images and to evaluate the sensitivity, specificity and false positive rate of the C-Vu CAD system for these chest exams
•VuCOMP will process lung nodule cases to estimate C-Vu's sensitivity.
•VuCOMP will process negative cases to estimate C-Vu's specificity and false positive rate.
•VuCOMP will process current and prior lung nodule cases to compare results.
The main purpose of this study is to is to determine the duration of survival in patients receiving trastuzumab at different dose levels in combination with standard doses of cisplatin and capecitabine. We want to find out how different doses of trastuzumab affect patients and their metastatic gastric cancer or GEJ cancer, and whether a higher dose of trastuzumab will increase blood levels of trastuzumab and provide more benefit than the currently approved dose. Therefore, to check how much trastuzumab circulates in the blood with different doses, we will investigate trastuzumab blood levels by taking blood samples at various times before and after trastuzumab doses. We will also look at tumor growth, the safety and how tolerable trastuzumab is given at both dose regimens. Also, the study will investigate the time from when trastuzumab dosing begins until the cancer starts re-growing, if that happens.
Pulmonary emphysema is associated with air trapping that compresses the diaphragm and causes shortness of breath. This research study will compare a lung volume reduction coil made by PneumRx with best supportive care (no treatment) to determine which group of participants can walk farther on a six-minute walk test at one year. The PneumRx RePneu Lung Volume Reduction Coil is a metal investigational device placed in lungs at the site of worst emphysema. The worst lobe in one lung is treated with coils at baseline and the other lung is treated four months later. Participants who do not receive coils may be eligible for a separate research study to receive coils at one year. This study has up to 14 visits over five years that must be performed at MUSC.
The main purpose of this study is to find out if the drug BKM120 is safe and has positive effects in people who have metastatic non-small cell lung cancer (NSCLC). The goal of this study is to find out if BKM120 has any effect in patients with non-small cell lung cancer with an activated PI3K pathway.
BKM120 is a medicine that has not been approved by the Food and Drug Administration for the treatment of people with this medical condition. BKM120 is currently not “on the market” in any country.
This study is designed to evaluate a new medication delivery technique to provide pain relief in the postoperative period following a VATS procedure. Participants in the study that receive the Paravertebral blocks in the study will either be assigned to a group of continuous or automated intermittent bolus infusion. The goal of the study is to discern whether one method of infusion is superior to the other in terms of controlling pain for patients undergoing the thoracotomy.
This is a randomized, Phase III, multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of MetMAb in combination with erlotinib as compared with treatment with erlotinib alone in patients with incurable NSCLC identified to be Met diagnostic positive.